Equities

Indofarma Tbk PT

INAF:JKT

Indofarma Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)268.00
  • Today's Change44.00 / 19.64%
  • Shares traded161.10k
  • 1 Year change-58.77%
  • Beta-0.3442
Data delayed at least 10 minutes, as of May 20 2024 10:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Indofarma Tbk is an Indonesia-based company, which is engaged in the healthcare industry. The Company's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The Company carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.

  • Revenue in IDR (TTM)684.91bn
  • Net income in IDR-437.05bn
  • Incorporated1996
  • Employees1.09k
  • Location
    Indofarma Tbk PTJl. Indofarma No. 1, Cikarang BaratBEKASI 17530IndonesiaIDN
  • Phone+62 2 188323971
  • Fax+62 2 188323972
  • Websitehttps://indofarma.id/en/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chiome Bioscience Inc65.87bn-132.87bn716.34bn51.00--5.54--10.87-25.56-25.5612.6022.390.33484.278.9612,602,040.00-67.53-50.50-88.83-57.3855.9657.53-201.70-224.743.46-629.880.2009--8.1926.241.84------
Veritas In Silico Inc-10.25tn-10.25tn718.09bn15.00--2.97----------363.52------------------------40.94--0.00--101.54--123.38------
Percheron Therapeutics Ltd6.67bn-115.86bn722.05bn8.00--4.11--108.27-0.0157-0.01570.00090.01820.0328--0.3224---56.94-72.09-66.58-81.73-----1,737.37-6,558.90----0.001--1,026.1672.03-95.81------
CellSeed Inc19.85bn-91.45bn736.07bn35.00--3.44--37.08-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
K Pharma Inc51.25bn-22.75bn737.44bn15.00--2.51--14.39-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60----------166.34------
Actinogen Medical Ltd3.60bn-158.79bn744.66bn----5.08--206.61-0.0073-0.00730.00020.00510.0211--0.7341---92.99-45.55-105.88-48.24-----4,405.86-5,369.76---294.930.0037--792.7431.88-13.21--166.95--
Indofarma Tbk PT684.91bn-437.05bn762.42bn1.09k------1.11-141.03-141.03221.00-33.990.41473.143.13578,473,800.00-26.46-6.07-75.37-12.29-25.7314.39-63.81-5.630.4962-15.511.16---60.58-6.85-1,040.12---32.32--
Data as of May 20 2024. Currency figures normalised to Indofarma Tbk PT's reporting currency: Indonesian Rupiah IDR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.